Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics in Development"
Ampio Pharmaceuticals, Inc. (AMPE) announced its participation at the ROTH Capital Healthcare Event, specifically the COVID-19 Therapeutics in Development webinar on October 28, 2020. This event replaces a previous announcement regarding the company’s involvement in the 2020 MedTech Innovation Forum. The webinar will focus on therapies in development for COVID-19, featuring sessions on immune modulators and antiviral agents. Ampio's future statements regarding therapeutic advancements and regulatory approvals remain forward-looking and subject to risks.
- Participation in a prominent healthcare event, enhancing visibility.
- Focus on COVID-19 therapies aligns with market needs.
- Dependence on future regulatory approvals introduces uncertainty.
- Forward-looking statements carry inherent risks that could affect performance.
ENGLEWOOD, Colo., Oct. 27, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it will present at the ROTH Capital Healthcare Event, "COVID-19 Therapeutics in Development" taking place on Wednesday, October 28, 2020 – 9:00 AM (ET) / 6:00 AM (PT). This corrects the previous announcement issued on October 26, 2020, which indicated that Ampio would be presenting at the 2020 MedTech Innovation Forum hosted by ROTH Capital.
The ROTH Healthcare and Biotechnology team are hosting the webinar to discuss key therapies in development to treat COVID disease.
The Webinar includes three sessions: "Immune Modulators to Ameliorate COVID Disease 1," "Direct Antivirals and Other Agents Against SARS-CoV2 Virus," and "Indirect Antivirals Against SARS-CoV2 Virus."
To register for the event, please click here.
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application ("BLA"), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Dan Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
Ampio Pharmaceuticals, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-present-at-the-roth-capital-healthcare-event-covid-19-therapeutics-in-development-301160562.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
When will Ampio Pharmaceuticals present at the ROTH Capital Healthcare Event?
What topics will be discussed during the ROTH Capital Healthcare Event?
What is the significance of the forward-looking statements in the press release by Ampio?
What previous event did Ampio Pharmaceuticals withdraw from?
